FDA – Page 54 – Policy & Medicine

CME Programs to Reduce Opioid Abuse

FDA Centers for Drug Evaluation and Research: Project Quicker Approval Pathways

FDA Strategic Plan to Address Drug Shortages, Solicitation for Comment

HHS OIG Report: FDA Lacks Comprehensive Data to Determine Whether Risk Evaluation and Mitigation Strategies (REMS) Improve Drug Safety

PCORI News Plus FDA Suggestions on Comparative Effectiveness Research

FDA: Enrichment Strategies to Improve Efficiency of Drug Development

FDA Updates PDUFA Goals: NDA’s, BLA’s and REMS

FDA Center for Drug and Evaluation Research Exclusivity Board, Data Partnership and Neoadjuvant Therapies

FDA Implementation Timeline and Tracking for the Food and Drug Administration, Safety and Innovation Act (FDASIA)

FDA REMS: Mycophenolate Class Wide REMS